Ipamorelin vs CJC-1295: Growth Hormone Secretagogues Compared

Two of the most-discussed growth-hormone-releasing peptides, side by side. Mechanisms, pulsatility, half-life, stacking logic, and what 2026 evidence actually supports.

Search any peptide forum for "growth hormone stack" and within five threads you will see the same two names: ipamorelin and CJC-1295. They are usually discussed together, sometimes treated as interchangeable, and frequently misrepresented. They are not interchangeable. They are not even the same class of compound, despite both being marketed as "GH peptides."

This is a head-to-head comparison written for non-specialists who want to understand what the molecules actually do, why people stack them, and what the evidence does and does not show. It is not a protocol guide, and it is not a recommendation.

Two different classes, one shared outcome

Both peptides increase endogenous growth hormone (GH) secretion. They do so by acting on different receptors in different parts of the pituitary axis.

Ipamorelin is a growth hormone secretagogue (GHS) — specifically, a selective agonist of the ghrelin receptor (GHS-R1a). It mimics the action of ghrelin on the anterior pituitary, triggering a pulse of GH release. Unlike older ghrelin agonists, ipamorelin is selective: it does not meaningfully elevate cortisol, prolactin, or aldosterone at standard doses. That selectivity is the main reason it became popular over GHRP-2 and GHRP-6.

CJC-1295 is a growth hormone releasing hormone (GHRH) analog. It binds to the GHRH receptor on somatotrophs in the anterior pituitary and prompts GH synthesis and release through the same pathway that endogenous GHRH uses. There are two distinct molecules sold under the CJC-1295 name, which matters enormously and which most marketing copy obscures.

The CJC-1295 / "DAC" problem

CJC-1295 comes in two versions that pharmacologically behave like different drugs.

CJC-1295 without DAC (also called modified GRF 1-29 or mod-GRF 1-29) is a short-acting GHRH analog with a half-life measured in roughly 30 minutes. It produces a fast, transient GH pulse and clears quickly.

CJC-1295 with DAC (Drug Affinity Complex) has a maleimide group attached that binds covalently to serum albumin. Its half-life extends to approximately 6–8 days. Rather than producing a pulse, it produces a sustained elevation in baseline GH and IGF-1 — a "bleed" rather than a "burst."

When forums say "CJC-1295" without specifying DAC, they are usually conflating two compounds with very different pharmacokinetics, very different effects on physiological pulsatility, and meaningfully different safety considerations. Any honest discussion has to separate them.

Quick reference comparison

Note: All references to dosing are descriptive of how these compounds are studied or discussed in published research and forum protocols. They are not recommendations. None of these peptides is FDA-approved for general use; ipamorelin and CJC-1295 are unapproved in the U.S. and not on the FDA's permitted compounding list under current Category 1/2 framework. See our FDA Peptide Status 2026 overview for context.

Why people stack them

The stacking logic — ipamorelin with CJC-1295 (no DAC) — is grounded in real pharmacology, not just marketing. The two compounds act on different receptors and produce a synergistic GH response when given together. Studies of similar GHRH-plus-GHS combinations (such as sermorelin with GHRP-2 or tesamorelin with a ghrelin mimetic) show GH peaks that exceed the sum of the two compounds given separately.

The mechanistic rationale: GHRH analogs increase the amplitude of a GH pulse by acting on somatotrophs, while ghrelin agonists both stimulate release and reduce somatostatin tone, which lifts the natural "brake" on GH secretion. When both arms are engaged at once, the resulting GH pulse is larger than either compound produces alone.

What the stack does not do is reliably replicate the GH curves of someone twenty years younger, and it does not produce the level of GH exposure achieved by exogenous recombinant GH. Marketing claims that conflate "increase GH" with "match the GH of youth" or "equal to GH therapy" are not supported by the comparative pharmacology.

Pulsatility matters

One reason the GHS/GHRH approach is biologically attractive — and one reason CJC-1295-with-DAC complicates the picture — is that the body releases GH in discrete pulses. Roughly every three to five hours, with the largest pulses overnight, healthy somatotrophs fire. The downstream effects of GH (on tissues, on IGF-1 production, on metabolism) are tuned to that pulsatile pattern, not to constant elevation.

Exogenous GH disrupts pulsatility. Sustained-release GHRH analogs like CJC-1295 with DAC also flatten pulsatility, even though they work through the body's own pituitary. Whether this flattening matters for the specific tissues you care about is unresolved. Some research suggests pulsatility-dependent gene expression in muscle and bone; some suggests the integrated GH/IGF-1 exposure is what matters and the shape of the curve is secondary. The honest answer in 2026 is that we do not have human longitudinal data that fully resolves this question for the peptide stacks people are actually using.

The practical implication: if preserving pulsatility is a goal, the no-DAC version is the only consistent choice. CJC-1295 with DAC is fundamentally a different intervention.

What the human data says

Ipamorelin was investigated by Novo Nordisk in Phase II trials for postoperative ileus in the 2000s. Those trials established a reasonable safety signal at the doses studied (single-digit milligrams IV in adults), but development was discontinued for efficacy reasons, not safety. Outside of that program, controlled human data on ipamorelin in healthy adults at the doses typically discussed in forums (low microgram subcutaneous, multiple times daily) is sparse.

CJC-1295 without DAC has limited published human data. Its parent molecule (sermorelin, GRF 1-29) has FDA approval history and a longer-running clinical record, but mod-GRF 1-29 specifically — the molecule sold as "CJC-1295 no-DAC" — is studied largely through extension from sermorelin and animal work.

CJC-1295 with DAC has the most published pharmacokinetic data of the three, including the original ConjuChem trials demonstrating sustained GH and IGF-1 elevation with weekly dosing. Long-term human safety data at the doses currently used in non-trial settings does not exist.

None of these compounds has the multi-thousand-patient pharmacovigilance record that semaglutide or tesamorelin has. See our Peptide Safety Guide for the framework on how to weigh this kind of evidence gap.

Side effect profile, honestly

The most commonly reported effects across both compounds, in research and forum self-reports, are:

• Injection site reactions (transient redness, mild swelling)
• Flushing — especially with GHRH analogs, related to histamine release
• Tingling or numbness in extremities, typically transient
• Increased hunger (especially with ipamorelin, which has weak orexigenic activity through ghrelin signaling)
• Fluid retention and mild peripheral edema — IGF-1-mediated and dose-dependent
• Headaches

The theoretical concerns that should be on every honest discussion's list:

• IGF-1 elevation in patients with undiagnosed or treated malignancy
• Insulin resistance with chronic, supraphysiological GH exposure — most relevant for CJC-1295 with DAC
• Pituitary feedback effects with prolonged daily stimulation
• Acromegaly-related symptoms (joint pain, soft tissue overgrowth) at supraphysiological doses

These are not common at the doses typically discussed for short cycles in healthy adults, but "uncommon" is doing a lot of work in a population without systematic monitoring.

How to read marketing claims

A few specific claims to scrutinize:

"Ipamorelin is the safest GH peptide." It is the most selective among ghrelin agonists, which is meaningful. "Safest" without specifying compared to what, at what dose, for how long, is marketing language.

"CJC-1295 mimics youthful GH levels." CJC-1295 increases GH and IGF-1. Whether the resulting exposure pattern resembles a younger person's profile depends on which version, at what dose, dosed how. With DAC, the pattern is closer to a constant infusion than a youthful pulsatile profile.

"This stack is FDA-approved." Neither compound is FDA-approved. As of 2026, both are listed in the FDA's Category 2 review framework for compounded peptides, with regulatory enforcement varying by state and pharmacy classification (see 503A and 503B definitions).

"More GH means more muscle and less fat." The dose-response curve for body composition effects of GH is non-linear and bounded. Past a certain GH/IGF-1 exposure, additional elevation produces side effects without proportional benefit. The peptide stack does not bypass that biology.

The bottom-line comparison

Ipamorelin and CJC-1295 are not redundant; they hit different receptors, and the rationale for stacking them is real. They are also not interchangeable with each other or with two different versions of "CJC-1295." If a discussion of these compounds does not distinguish between mod-GRF 1-29 and CJC-1295 with DAC, that discussion is starting from a confused premise.

The human evidence base for both compounds, at the doses they are typically used outside clinical trials, is thin compared to peptides like semaglutide, tirzepatide, or even tesamorelin. The mechanistic story is interesting; the longitudinal safety story is unwritten. Both compounds remain unapproved by the FDA and outside the current compounding-permitted lists.

For non-specialists, the most useful framing is probably this: these are interesting research molecules whose pharmacology is reasonably well understood and whose long-term effects in healthy adults using forum-style protocols are not. That gap is the whole story. Anyone selling you certainty about either compound — for or against — is doing marketing, not science.

Further reading on PeptideAdvance

• Ipamorelin peptide page
• CJC-1295 peptide page
• GHRH glossary entry
• Ghrelin glossary entry
• IGF-1 glossary entry
• Peptide Safety Guide
• FDA Peptide Status 2026